Latest Breaking News On - Annual scientific - Page 10 : comparemela.com

SMART trial shows comparable outcomes of two common TAVR devices in small aortic annulus patients

People with a small aortic annulus, a part of the heart's anatomy where the left ventricle meets the aorta, who underwent transcatheter aortic valve replacement (TAVR) with a supra-annular self-expanding valve saw similar clinical outcomes and superior valve performance at one year compared with those who underwent TAVR with a balloon-expandable valve, according to research presented at the American College of Cardiology's Annual Scientific Session.

United statesJohnw bryfogleHowardc herrmannAmerican college of cardiologyHospital of the university pennsylvaniaUniversity of pennsylvaniaMedtronic incAmerican college of cardiology annual scientific sessionPerelman school of medicineAmerican collegeAnnual scientificCardiovascular medicinePerelman schoolNorth americaNew england journalTranscatheter aortic valve replacement

Plozasiran reduces triglyceride levels by 74% at 24 weeks

Plozasiran reduces triglyceride levels by 74% at 24 weeks
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Daniel gaudetAmerican college of cardiology annual scientific sessionUniversity of montrealAmerican collegeAnnual scientific

Chelation therapy does not improve outcomes after heart attack

Chelation therapy does not improve outcomes after heart attack
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican college of cardiology annual scientific sessionDrug administrationAmerican collegeAnnual scientificColumbia university divisionMount sinai medical centerNorth americaWestern europe

Ninerafaxstat well-tolerated and safe for nonobstructive hypertrophic cardiomyopathy

Ninerafaxstat well-tolerated and safe for nonobstructive hypertrophic cardiomyopathy
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesMartins maronAmerican college of cardiology annual scientific sessionHypertrophic cardiomyopathy center at lahey hospitalAmerican collegeAnnual scientificHypertrophic cardiomyopathy centerLahey hospitalMedical centerKansas city cardiomyopathy questionnairesNovel cardiac mitotrope

Investigational drug plozasiran shows promise in reducing severe hypertriglyceridemia

In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology's Annual Scientific Session.

Daniel gaudetArrowhead pharmaceuticalsUniversity of montrealAmerican college of cardiology annual scientific sessionAmerican college of cardiologyAmerican collegeAnnual scientificAcute pancreatitis